Vaccine against Covid-19: the clinical trial of Johnson & Johnson to resume

Doses of the vaccine developed by the Johnson & Johnson laboratory.

Currently in phase 3, the clinical trial of this candidate vaccine against Covid-19 must resume.

Cheryl Gerber / Johnson & Johnson via AP

Text by: RFI Follow

3 min

He had been interrupted a few days ago.

The clinical trial of the candidate vaccine from the American laboratory Johnson & Johnson is expected to resume shortly.

Paused following a "serious medical event" in a patient, the company indeed announces that it has found no element implicating the vaccine.


Read more

Almost two weeks after its interruption, the recruitment campaign for the phase 3 clinical trial of Johnson & Johnson's vaccine candidate is expected to resume in a few days.

The American firm announces in fact that it has found " 

no evidence

 " that its vaccine was responsible for an adverse event in one of the volunteers.

A total of 60,000 people are expected to take part in this trial.

The other test that must be resumed in the United States is the one developed jointly by the AstraZeneca laboratory and the University of Oxford.

Interrupted in September

for similar reasons, the enrollment of patients had however recommenced a few days later in the world, except in the United States, the only country where the authorities had maintained this suspension until a green light given on Friday.

Two more advanced candidates

These two vaccine candidates are among the most advanced in their development.

They are ten in total to have entered phase 3 of clinical trials, the last before the vaccine is marketed.

Two other American laboratories, Pfizer and


, are also planning to apply for marketing authorization from the American health authorities towards the end of November.

This progress gives hope that at least one of them will be available by the end of the year. 

Our selection on the coronavirus

Listen to our

Coronavirus Info






What are the persistent symptoms of Covid-19?


Young people and Covid-19

: health authorities concerned


Immunity to Covid-19 would be short-lived


Promising results for the vaccine against the coronavirus

How to make a mask and use it well

See also the



RFI Knowledge

on Covid-19


Birth of a pandemic


Daily proof


The history of epidemics


Science facing Covid-19


The geopolitical consequences


Receive all the international news directly in your mailbox

I subscribe

Follow all the international news by downloading the RFI application


  • Coronavirus

  • United States

  • Health and medicine

On the same subject

Vaccine against Covid-19: the mistrust of the population threatens the fight against the pandemic

Covid-19: Trump's rush for vaccine worries Democrats

Vaccine against Covid-19: the American company Moderna finalizes its clinical trial